Newsroom | 48473 results

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Parabilis Medicines shares preliminary clinical data demonstrating the therapeutic potential of its lead investigational candidate, FOG-001, in ACP....

IRVINE, Calif.--(BUSINESS WIRE)--Immunis, Inc., a clinical-stage biotech pioneering multi-active stem cell-derived biologics for age and disease-related immune dysregulation, today announced it has been named one of the Top 50 Healthcare Technology Companies of 2025 by The Healthcare Technology Report, recognizing notable advances in next-generation therapeutics, care delivery and clinical insights. The recognition follows the company’s recent publication in Obesity showing body fat loss and in...

ATHENS, Ga. & SAN JOSE, Calif.--(BUSINESS WIRE)--Blue Lake Biotechnology, Inc., a clinical-stage intranasal vaccine company developing parainfluenza virus 5 (PIV5)-vectored vaccines that harness the full breadth of the immune system to protect against serious infectious diseases, today announced that it has secured written agreement from the U.S. Food and Drug Administration (FDA) to resume dosing of BLB201, the company’s investigational RSV vaccine, in children as young as 18 months who are RS...

MILAN--(BUSINESS WIRE)--On the heels of AAVantgarde closing a Series B financing round, AGC Biologics announced a new manufacturing agreement with the biotechnology company, marking AGC Biologics’ latest advancement in the adeno-associated virus market. Under this agreement, AGC Biologics will provide Good Manufacturing Practice manufacturing for AAVantgarde’s two novel candidates designed to address progressive and irreversible vision loss where there are currently no approved therapies: AAVB-...

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a clinical-stage precision oncology company, today announced that following the announcement on November 14, 2025 of the entering into of a definitive arrangement agreement with XenoTherapeutics, Inc. and Xeno Acquisition Corp. (jointly, “Xeno”), a non-profit biotechnology company, pursuant to which Xeno will acquire (the “Transaction”) all of the issued and outstanding common shar...

SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today reported topline data from its Phase 2 VISTA trial of PIPE-307, an M1 receptor antagonist, in development for the treatment of patients with relapsing-remitting multiple sclerosis (RRMS). The trial demonstrated acceptable safet...

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate in a fireside chat at Citi’s 2025 Global Healthcare Conference on Tuesday, December 2, 2025 at 9:45 a.m. Eastern Time. A live webcast of Acadia’s fireside chat will be accessible on the company’s website, acadia.com, under the investors section and an archived recording will be available on the website for approximately one month following the presentation. About Acadia Pharmaceutical...

TEL AVIV, Israel--(BUSINESS WIRE)--Cassidy Bio, ein Biotechnologieunternehmen und Entwickler des ersten KI-gestützten Genom-Basismodells zur Optimierung von Genom-Editierungs-Therapien, gab heute seine Gründung und den Abschluss einer Seed-Finanzierungsrunde in Höhe von 8 Millionen US-Dollar bekannt. Mit der Finanzierung wird das Unternehmen seine Plattform weiterentwickeln. Diese wurde als holistische Lösung konzipiert, um Präzision, Geschwindigkeit und klinische Verlässlichkeit in den rasant...

TEL AVIV, Israele--(BUSINESS WIRE)--Cassidy Bio, azienda biotecnologica impegnata nello sviluppo del primo modello di base genomica basato sull'AI nell'obiettivo di migliorare la progettazione di terapie di editing genetico, oggi annuncia il lancio e la chiusura di un round di finanziamento seed del valore di 8 milioni di dollari USA. L'azienda utilizzerà questo capitale per sviluppare la propria piattaforma, ideata come soluzione olistica per portare precisione, velocità e sicurezza clinica ne...

TEL AVIV, Israël--(BUSINESS WIRE)--Cassidy Bio, een biotechnologiebedrijf dat het eerste AI-gestuurde genomische basismodel ontwikkelt om het ontwerp van genbewerkingstherapieën te verbeteren, heeft vandaag de lancering en de afronding van een startkapitaalronde van $ 8 miljoen aangekondigd. Het bedrijf zal de financiering gebruiken om zijn platform verder te ontwikkelen, dat is gebouwd als een holistische oplossing die precisie, snelheid en klinisch vertrouwen biedt in het snelgroeiende veld v...